The TAA supports clinical research and clinical studies to improve the quality of life for those affected by Tourette Syndrome. The studies below are listed for informational purposes only and are not being conducted by TAA, nor is any relationship being claimed between TAA and the study teams by virtue of their inclusion on this list.
Visit www.clinicaltrials.gov for a more comprehensive list of opportunities to participate in research studies in your area. For information on non-clinical research studies, visit our Research Studies page.
To list an IRB-approved study on this page, please submit your study via the instructions below. Please note that TAA can only receive requests for posting directly from the study sponsor.
Open Clinical Studies for Tourette Syndrome and Tic Disorders
The following studies are open and actively recruiting participants. Please see the description associated with each study to learn more about what is being investigated. Each study’s description also includes either an external link (which will take you away from our TAA website) or contact information, should you wish to participate in a study.
Click the plus sign (+) below to learn more about each study.
Allevia 2 Study
Noema Pharma – Various Sites
The Allevia 2 study, a clinical study exploring the safety and efficacy of gemlapodect on tics associated with Tourette Syndrome, is ongoing in several centers in the US and in European countries.
The phase 2b Allevia 2 (NOE-TTS-201) study aims to determine whether Gemlapodect is a safe and efficacious therapy for patients with Tourette Syndrome compared to those currently available. (Gemlapodect is a potential drug that is currently in development, also called an investigational drug, meaning it has not yet been approved by the United States Food and Drug Administration (FDA), or other regulatory agencies around the world for use by the general public). Tourette Syndrome affects millions of children, adolescents, and adults around the world, and the currently approved therapies for this condition can sometimes have unwanted side effects.
Before initiating this clinical study, gemlapodect has been tested in previous clinical studies, including a first trial (Allevia 1, NOE-TTS-211) in patients with Tourette Syndrome. The Allevia 1 and Allevia 2 studies are sponsored by Noema Pharma.
To learn more about this study and potential eligibility for participation, please visit this link.
Mindfulness-Based Intervention for Tics (MBIT)
Johns Hopkins Medical University
In response to the critical need for new safe, efficacious, and accessible treatment options for adults with TS, our team (Drs. Reese and McGuire, and Mr. Brown) will be conducting a large, NIH-funded clinical trial to test a Mindfulness-based Intervention for Tics (MBIT) in 150 adults with TS who have moderate or greater tic severity. In the pilot clinical trial, funded by the TAA, Dr. Reese compared group MBIT to group psychoeducation, relaxation, and supportive therapy (PRST) in adults with TS. Both interventions were delivered remotely to improve the accessibility of care. MBIT was found to be feasible, acceptable, and efficacious for reducing tic severity and impairment relative to PRST. This intervention and its remote group delivery approach offer a practical, scalable, and sustainable solution that hopes to improve therapeutic outcomes for adults with TS. Individuals with TS interested in participating should visit this link to learn more and engage.
The TReC Study
University of Minnesota
The purpose of the TReC study is to identify who is most likely to benefit from CBIT, how CBIT changes the brain,, and which parts of CBIT sessions are more helpful. This study will look at changes in tics over the course of treatment. By using neuroimaging methods such as EEG and fMRI, this study will add to the field’s understanding of the neurological mechanisms that take place during CBIT and will assess which CBIT factors are more important for reducing tic symptoms.
Participants will undergo behavioral and clinical assessments prior to starting the CBIT treatment, right after completing treatment, and three months after their last treatment visit. Participants will also undergo an EEG and MRI before and after completing their CBIT sessions.
Participants will complete eight weekly in-person CBIT sessions over 10 weeks at the Masonic Institute for the Developing Brain. Participants will complete a brief Tic Suppression Task at each session. Each CBIT visit is expected to take 1 hour. Overall, participation will take place over 27 weeks.
All participants will be compensated for their time.
CBIT + TMS
University of Minnesota
The CBIT + TMS Study is an in-person clinical trial at the University of Minnesota conducted by the Minnesota Tic and Compulsivity Lab (MnTiC). Individuals who have tics and are 12-21 years old may be eligible to participate. The goal of the CBIT+TMS Study is to test if Transcranial Magnetic Stimulation (TMS) can help make Comprehensive Behavioral Intervention for Tics (CBIT) more effective. CBIT is a recommended treatment for tics, but it only works for about 50% of people who receive it. Our research team wants to know if pairing CBIT with TMS can improve treatment outcomes.
Research participation includes 5 assessment visits, 10 daily in-person CBIT+TMS sessions along with 3 MRI visits at the University of Minnesota. Participants are compensated up to $460 for completing all study visits. For more information, please complete a study interest form or email us at ticlab@umn.edu.
Submit a Clinical Trial for Inclusion
Is your team conducting a study or trial that focuses on Tourette Syndrome or Tic Disorders and would like us to list it here? Thank you for your work! Please fill out the form below. Our team will review and then get in touch with any questions before listing your opportunity.
